Pfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.
Follow PFE
Pfizer Inc. (PFE) EPS (diluted)
Pfizer Inc.'s EPS (diluted) for fiscal 2025 was $1.36, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $0.76. Over the past ten years it has ranged from $0.37 (fiscal 2023) to $5.47 (fiscal 2022); the current reading is higher than 36% of that period. Pfizer Inc. ranks 15th of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $1.36 | (3.55%) |
| FY2024 | $1.41 | 281.08% |
| FY2023 | $0.37 | (93.24%) |
| FY2022 | $5.47 | 42.08% |
| FY2021 | $3.85 | 125.15% |
| FY2020 | $1.71 | (40.42%) |
| FY2019 | $2.87 | 53.48% |
| FY2018 | $1.87 | (46.87%) |
| FY2017 | $3.52 | 200.85% |
| FY2016 | $1.17 | (5.65%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.04 | — |
| Mar 2026 | $0.47 | — |
| Dec 2025 | −$0.29 | — |
| Sep 2025 | $0.62 | 21.57% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AMGN Amgen Inc. compare | $16.09 |
| AZN AstraZeneca PLC compare | $6.69 |
| NVS Novartis AG compare | $6.63 |
| BMY Bristol Myers Squibb Company compare | $4.54 |
| NVO Novo Nordisk A/S compare | $4.09 |
| GSK GSK PLC Sponsored ADR compare | $3.20 |
| SNY Sanofi compare | $1.91 |
| PFE Pfizer Inc. | $0.76 |
| GILD Gilead Sciences, Inc. compare | −$2.67 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on PFE
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement